Skip to main content
Erschienen in: Familial Cancer 2/2012

01.06.2012 | Original Article

Predictive genetic testing of first degree relatives of mutation carriers is a cost-effective strategy in preventing hereditary non-polyposis colorectal cancer in Singapore

verfasst von: Vivian Wei Wang, Poh Koon Koh, Wai Leng Chow, Jeremy Fung Yen Lim

Erschienen in: Familial Cancer | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer (CRC) is the most common cancer in Singapore. We sought to evaluate the long-term cost-effectiveness of targeted genetic testing and surveillance programs in individuals at high risk of hereditary non-polyposis colorectal cancer (HNPCC), as compared to an unselective clinical surveillance program alone in Singapore. A Markov model analysis from the healthcare service provider’s perspective was developed to follow over a lifetime a cohort of cancer-free 21-year-old individuals, who were first-degree relatives of HNPCC patients with a known mutation. Genetic testing strategy provided a lifetime saving of Singapore dollars (SGD) 13,588 per person and gained additional life years of 0.01, as compared to clinical surveillance alone, by sparing non-mutation carriers from unnecessary and invasive intensive clinical surveillance (assuming 100% compliance with recommended surveillance programs in both strategies). Sensitivity analyses showed that as long as the compliance rate in mutation carriers was not lower than that for individuals without genetic testing, pursuing a genetic testing strategy would either be a more favorable option with discounted incremental cost-effectiveness ratios ranging from SGD 6,961 to 17,289 per life year gained or a dominant status achieved (more life year gained and less costly). Genetic testing for individuals at high risk of HNPCC allows targeted clinical surveillance to be directed at mutation carriers, ensuring efficient use of healthcare resources and reduces CRC-related mortality. It can be regarded as a cost-effective strategy in Singapore, if an improved compliance with recommended surveillance protocol is achieved in proven mutation carriers.
Literatur
2.
Zurück zum Zitat Aaltonen LA, Salovaara R, Kristo P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338(21):1481–1487PubMedCrossRef Aaltonen LA, Salovaara R, Kristo P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338(21):1481–1487PubMedCrossRef
3.
Zurück zum Zitat Lamberti C, Mangold E, Pagenstecher C et al (2006) Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany. Digestion 74(1):58–67PubMedCrossRef Lamberti C, Mangold E, Pagenstecher C et al (2006) Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany. Digestion 74(1):58–67PubMedCrossRef
4.
Zurück zum Zitat Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348(10):919–932PubMedCrossRef Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348(10):919–932PubMedCrossRef
5.
Zurück zum Zitat Marra G, Boland CR (1995) Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 87(15):1114–1125PubMedCrossRef Marra G, Boland CR (1995) Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 87(15):1114–1125PubMedCrossRef
6.
Zurück zum Zitat Watson P, Lynch HT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71(3):677–685PubMedCrossRef Watson P, Lynch HT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71(3):677–685PubMedCrossRef
7.
8.
Zurück zum Zitat Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214–218PubMedCrossRef Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214–218PubMedCrossRef
9.
Zurück zum Zitat Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129(2):415–421PubMed Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129(2):415–421PubMed
10.
Zurück zum Zitat Lynch HT, Smyrk TC, Watson P et al (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104(5):1535–1549PubMed Lynch HT, Smyrk TC, Watson P et al (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104(5):1535–1549PubMed
11.
Zurück zum Zitat Koh PK, Chew MH, Tan YS et al. (2010) Preliminary results of mismatch repair deficiency screening via immunohistochemical staining in young Asian colorectal cancers. In: Ling KL (ed) Proceedings of Singapore healthcare, vol 19, (1). pp 3–11 Koh PK, Chew MH, Tan YS et al. (2010) Preliminary results of mismatch repair deficiency screening via immunohistochemical staining in young Asian colorectal cancers. In: Ling KL (ed) Proceedings of Singapore healthcare, vol 19, (1). pp 3–11
13.
Zurück zum Zitat Stanley AJ, Gaff CL, Aittomaki AK et al (2000) Value of predictive genetic testing in management of hereditary non-polyposis colorectal cancer (HNPCC). Med J Aust 172(7):313–316PubMed Stanley AJ, Gaff CL, Aittomaki AK et al (2000) Value of predictive genetic testing in management of hereditary non-polyposis colorectal cancer (HNPCC). Med J Aust 172(7):313–316PubMed
14.
Zurück zum Zitat Loader S, Shields C, Rowley PT (2005) Impact of genetic counseling and DNA testing on individuals with colorectal cancer with a positive family history: a population-based study. Genet Test 9(4):313–319PubMedCrossRef Loader S, Shields C, Rowley PT (2005) Impact of genetic counseling and DNA testing on individuals with colorectal cancer with a positive family history: a population-based study. Genet Test 9(4):313–319PubMedCrossRef
15.
Zurück zum Zitat Lynch HT, Watson P, Shaw TG et al (1999) Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: hereditary nonpolyposis colorectal carcinoma as a model. Cancer 86(11 Suppl):2457–2463PubMedCrossRef Lynch HT, Watson P, Shaw TG et al (1999) Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: hereditary nonpolyposis colorectal carcinoma as a model. Cancer 86(11 Suppl):2457–2463PubMedCrossRef
16.
Zurück zum Zitat Dinh TA, Rosner BI, Atwood JC et al. (2011) Health benefits and cost-effectiveness of primary genetic screening for lynch syndrome in the general population. Cancer Prev Res (Phila) 4(1):9–22 Dinh TA, Rosner BI, Atwood JC et al. (2011) Health benefits and cost-effectiveness of primary genetic screening for lynch syndrome in the general population. Cancer Prev Res (Phila) 4(1):9–22
17.
Zurück zum Zitat Kievit W, de Bruin JH, Adang EM et al (2005) Cost effectiveness of a new strategy to identify HNPCC patients. Gut 54(1):97–102PubMedCrossRef Kievit W, de Bruin JH, Adang EM et al (2005) Cost effectiveness of a new strategy to identify HNPCC patients. Gut 54(1):97–102PubMedCrossRef
18.
Zurück zum Zitat Ramsey SD, Burke W, Clarke L (2003) An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med 5(5):353–363PubMedCrossRef Ramsey SD, Burke W, Clarke L (2003) An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med 5(5):353–363PubMedCrossRef
19.
Zurück zum Zitat Ramsey SD, Clarke L, Etzioni R et al (2001) Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 135(8 Pt 1):577–588PubMed Ramsey SD, Clarke L, Etzioni R et al (2001) Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 135(8 Pt 1):577–588PubMed
20.
Zurück zum Zitat Reyes CM, Allen BA, Terdiman JP, Wilson LS (2002) Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer 95(9):1848–1856PubMedCrossRef Reyes CM, Allen BA, Terdiman JP, Wilson LS (2002) Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer 95(9):1848–1856PubMedCrossRef
21.
Zurück zum Zitat Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM (1998) Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 129(10):787–796PubMed Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM (1998) Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 129(10):787–796PubMed
22.
Zurück zum Zitat Vasen HF, van Ballegooijen M, Buskens E et al (1998) A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 82(9):1632–1637PubMedCrossRef Vasen HF, van Ballegooijen M, Buskens E et al (1998) A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 82(9):1632–1637PubMedCrossRef
23.
Zurück zum Zitat Olsen KR, Bojesen SE, Gerdes AM, Lindorff-Larsen K, Bernstein IT (2007) Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health Care 23(1):89–95PubMedCrossRef Olsen KR, Bojesen SE, Gerdes AM, Lindorff-Larsen K, Bernstein IT (2007) Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health Care 23(1):89–95PubMedCrossRef
24.
Zurück zum Zitat Breheny N, Geelhoed E, Goldblatt J, Ee H, O’Leary P (2006) Economic evaluation of the familial cancer programme in Western Australia: predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma. Commun Genet 9(2):98–106CrossRef Breheny N, Geelhoed E, Goldblatt J, Ee H, O’Leary P (2006) Economic evaluation of the familial cancer programme in Western Australia: predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma. Commun Genet 9(2):98–106CrossRef
25.
Zurück zum Zitat Jenkins MA, Baglietto L, Dowty JG et al (2006) Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 4(4):489–498PubMedCrossRef Jenkins MA, Baglietto L, Dowty JG et al (2006) Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 4(4):489–498PubMedCrossRef
27.
Zurück zum Zitat Jarvinen HJ, Mecklin JP, Sistonen P (1995) Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108(5):1405–1411PubMedCrossRef Jarvinen HJ, Mecklin JP, Sistonen P (1995) Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108(5):1405–1411PubMedCrossRef
28.
Zurück zum Zitat Wagner J, Tunis S, Brown M, Ching A, Almeida R (1996) Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Young G, Rozen P, Levin B (eds) Prevention and early detection of colorectal cancer. Saunders, London, pp 321–356 Wagner J, Tunis S, Brown M, Ching A, Almeida R (1996) Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Young G, Rozen P, Levin B (eds) Prevention and early detection of colorectal cancer. Saunders, London, pp 321–356
29.
Zurück zum Zitat Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329(27):1977–1981PubMedCrossRef Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329(27):1977–1981PubMedCrossRef
30.
Zurück zum Zitat Winawer SJ, Zauber AG, O’Brien MJ et al (1993) Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 328(13):901–906PubMedCrossRef Winawer SJ, Zauber AG, O’Brien MJ et al (1993) Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 328(13):901–906PubMedCrossRef
31.
Zurück zum Zitat Vasen HF, Mecklin JP, Watson P et al (1993) Surveillance in hereditary nonpolyposis colorectal cancer: an international cooperative study of 165 families. The International Collaborative Group on HNPCC. Dis Colon Rectum 36(1):1–4PubMedCrossRef Vasen HF, Mecklin JP, Watson P et al (1993) Surveillance in hereditary nonpolyposis colorectal cancer: an international cooperative study of 165 families. The International Collaborative Group on HNPCC. Dis Colon Rectum 36(1):1–4PubMedCrossRef
32.
Zurück zum Zitat Wong SS, Leong AP, Leong TY (2004) Cost-effectiveness analysis of colorectal cancer screening strategies in Singapore: a dynamic decision analytic approach. Stud Health Technol Inform 107(Pt 1):104–110PubMed Wong SS, Leong AP, Leong TY (2004) Cost-effectiveness analysis of colorectal cancer screening strategies in Singapore: a dynamic decision analytic approach. Stud Health Technol Inform 107(Pt 1):104–110PubMed
34.
Zurück zum Zitat Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes. Oxford medical publications, 3rd edn. Oxford University Press, Oxford Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes. Oxford medical publications, 3rd edn. Oxford University Press, Oxford
35.
Zurück zum Zitat Making choices in health: WHO guide to cost-effectiveness analysis (2003). World Health Organization, Geneva Making choices in health: WHO guide to cost-effectiveness analysis (2003). World Health Organization, Geneva
36.
Zurück zum Zitat Vasen HF, Moslein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353–362PubMedCrossRef Vasen HF, Moslein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353–362PubMedCrossRef
37.
Zurück zum Zitat Jarvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829–834PubMedCrossRef Jarvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829–834PubMedCrossRef
38.
Zurück zum Zitat Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ (2000) Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 24(2):137–142PubMed Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ (2000) Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 24(2):137–142PubMed
39.
Zurück zum Zitat Bourne TH, Whitehead MI, Campbell S et al (1991) Ultrasound screening for familial ovarian cancer. Gynecol Oncol 43(2):92–97PubMedCrossRef Bourne TH, Whitehead MI, Campbell S et al (1991) Ultrasound screening for familial ovarian cancer. Gynecol Oncol 43(2):92–97PubMedCrossRef
40.
Zurück zum Zitat Korhonen MO, Symons JP, Hyde BM, Rowan JP, Wilborn WH (1997) Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 176(2):377–380PubMedCrossRef Korhonen MO, Symons JP, Hyde BM, Rowan JP, Wilborn WH (1997) Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 176(2):377–380PubMedCrossRef
41.
Zurück zum Zitat Langer RD, Pierce JJ, O’Hanlan KA et al (1997) Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med 337(25):1792–1798PubMedCrossRef Langer RD, Pierce JJ, O’Hanlan KA et al (1997) Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med 337(25):1792–1798PubMedCrossRef
42.
Zurück zum Zitat Lanspa SJ, Lynch HT, Smyrk TC et al (1990) Colorectal adenomas in the Lynch syndromes. Results of a colonoscopy screening program. Gastroenterology 98(5 Pt 1):1117–1122PubMed Lanspa SJ, Lynch HT, Smyrk TC et al (1990) Colorectal adenomas in the Lynch syndromes. Results of a colonoscopy screening program. Gastroenterology 98(5 Pt 1):1117–1122PubMed
43.
Zurück zum Zitat Mecklin JP, Jarvinen HJ (1986) Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum 29(3):160–164PubMedCrossRef Mecklin JP, Jarvinen HJ (1986) Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum 29(3):160–164PubMedCrossRef
44.
Zurück zum Zitat Mecklin JP, Sipponen P, Jarvinen HJ (1986) Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum 29(12):849–853PubMedCrossRef Mecklin JP, Sipponen P, Jarvinen HJ (1986) Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum 29(12):849–853PubMedCrossRef
46.
Zurück zum Zitat Van Bebber SL, Liang S-Y, Phillips KA et al (2007) Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk. Pers Med 4(3):341–350CrossRef Van Bebber SL, Liang S-Y, Phillips KA et al (2007) Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk. Pers Med 4(3):341–350CrossRef
47.
Zurück zum Zitat Esplen MJ, Madlensky L, Butler K et al (2001) Motivations and psychosocial impact of genetic testing for HNPCC. Am J Med Genet 103(1):9–15PubMedCrossRef Esplen MJ, Madlensky L, Butler K et al (2001) Motivations and psychosocial impact of genetic testing for HNPCC. Am J Med Genet 103(1):9–15PubMedCrossRef
48.
Zurück zum Zitat Kolata G (1998) Genetic testing falls short of public embrace. The New York times, 27 March 1998, p A16 Kolata G (1998) Genetic testing falls short of public embrace. The New York times, 27 March 1998, p A16
49.
Zurück zum Zitat Lerman C, Hughes C, Trock BJ et al (1999) Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 281(17):1618–1622PubMedCrossRef Lerman C, Hughes C, Trock BJ et al (1999) Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 281(17):1618–1622PubMedCrossRef
50.
Zurück zum Zitat Davey A, Rostant K, Harrop K, Goldblatt J, O’Leary P (2005) Evaluating genetic counseling: client expectations, psychological adjustment and satisfaction with service. J Genet Couns 14(3):197–206PubMedCrossRef Davey A, Rostant K, Harrop K, Goldblatt J, O’Leary P (2005) Evaluating genetic counseling: client expectations, psychological adjustment and satisfaction with service. J Genet Couns 14(3):197–206PubMedCrossRef
51.
Zurück zum Zitat Winawer SJ, Fletcher RH, Miller L et al (1997) Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 112(2):594–642PubMedCrossRef Winawer SJ, Fletcher RH, Miller L et al (1997) Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 112(2):594–642PubMedCrossRef
52.
Zurück zum Zitat Sonnenberg A, Delco F, Inadomi JM (2000) Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 133(8):573–584PubMed Sonnenberg A, Delco F, Inadomi JM (2000) Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 133(8):573–584PubMed
Metadaten
Titel
Predictive genetic testing of first degree relatives of mutation carriers is a cost-effective strategy in preventing hereditary non-polyposis colorectal cancer in Singapore
verfasst von
Vivian Wei Wang
Poh Koon Koh
Wai Leng Chow
Jeremy Fung Yen Lim
Publikationsdatum
01.06.2012
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2012
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-012-9513-y

Weitere Artikel der Ausgabe 2/2012

Familial Cancer 2/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.